Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Elvitegravir> ?p ?o. }
Showing items 1 to 73 of
73
with 100 items per page.
- Elvitegravir abstract "Elvitegravir (EVG, formerly GS-9137) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.".
- Elvitegravir atcPrefix "J05".
- Elvitegravir atcSuffix "AX11".
- Elvitegravir casNumber "697761-98-1".
- Elvitegravir chEBI "72289".
- Elvitegravir fdaUniiCode "4GDQ854U53".
- Elvitegravir iupacName "6-[(3-Chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid".
- Elvitegravir pubchem "5277135".
- Elvitegravir thumbnail Elvitegravir_structure.svg?width=300.
- Elvitegravir wikiPageID "14767972".
- Elvitegravir wikiPageRevisionID "594718446".
- Elvitegravir atcPrefix "J05".
- Elvitegravir atcSuffix "AX11".
- Elvitegravir c "23".
- Elvitegravir casNumber "697761".
- Elvitegravir chebi "72289".
- Elvitegravir chembl "204656".
- Elvitegravir chemspiderid "4441060".
- Elvitegravir cl "1".
- Elvitegravir eliminationHalfLife "46440.0".
- Elvitegravir excretion "liver 93%, renal 7%".
- Elvitegravir f "1".
- Elvitegravir h "23".
- Elvitegravir hasPhotoCollection Elvitegravir.
- Elvitegravir image "Elvitegravir3D.PNG".
- Elvitegravir inchi "1".
- Elvitegravir inchikey "JUZYLCPPVHEVSV-LJQANCHMBZ".
- Elvitegravir iupacName "6".
- Elvitegravir metabolism "liver, via CYP3A".
- Elvitegravir molecularWeight "447.883".
- Elvitegravir n "1".
- Elvitegravir niaidChemdb "241767".
- Elvitegravir o "5".
- Elvitegravir pregnancyUs "B".
- Elvitegravir proteinBound "98.0".
- Elvitegravir pubchem "5277135".
- Elvitegravir routesOfAdministration "oral".
- Elvitegravir smiles "Clc1ccccCc3ccc2cc3".
- Elvitegravir stdinchi "1".
- Elvitegravir stdinchikey "JUZYLCPPVHEVSV-LJQANCHMSA-N".
- Elvitegravir tradename tenofovir.
- Elvitegravir unii "4".
- Elvitegravir verifiedfields "changed".
- Elvitegravir verifiedrevid "437144022".
- Elvitegravir watchedfields "changed".
- Elvitegravir subject Category:Integrase_inhibitors.
- Elvitegravir subject Category:Japan_Tobacco.
- Elvitegravir subject Category:Organochlorides.
- Elvitegravir subject Category:Organofluorides.
- Elvitegravir subject Category:Quinolines.
- Elvitegravir type Inhibitor114724436.
- Elvitegravir type IntegraseInhibitors.
- Elvitegravir type Matter100020827.
- Elvitegravir type PhysicalEntity100001930.
- Elvitegravir type Substance100020090.
- Elvitegravir type Drug.
- Elvitegravir type DrugProduct.
- Elvitegravir type FunctionalSubstance.
- Elvitegravir comment "Elvitegravir (EVG, formerly GS-9137) is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by U.S.".
- Elvitegravir label "Elvitegravir".
- Elvitegravir label "Elvitegravir".
- Elvitegravir label "Elvitegravir".
- Elvitegravir label "Elvitégravir".
- Elvitegravir sameAs Elvitégravir.
- Elvitegravir sameAs Elvitegravir.
- Elvitegravir sameAs Elvitegravir.
- Elvitegravir sameAs m.03gxb08.
- Elvitegravir sameAs Q2740966.
- Elvitegravir sameAs Q2740966.
- Elvitegravir sameAs Elvitegravir.
- Elvitegravir wasDerivedFrom Elvitegravir?oldid=594718446.
- Elvitegravir depiction Elvitegravir_structure.svg.
- Elvitegravir isPrimaryTopicOf Elvitegravir.
